Olaris Presenting at SABCS 2021: Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients
December 6, 2021
Olaris presented new data on the identification of metabolic signatures in matched plasma and serum samples associated with tumor proliferation in early-stage breast cancer (eBC) patients treated with Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) at the upcoming San Antonio Breast Cancer Symposium® to be held December 7-10, 2021. The presentation, conducted in collaboration with Dr. Cynthia Ma, Professor of Medicine, Division of Oncology at Washington University in St. Louis, highlights the use of Olaris’ BoR platform to identify metabolic signatures associated with tumor proliferation, an indicator of treatment resistance, in eBC patients treated with CDK4/6i.
Olaris Attending HLTH 2021 in Boston with Microsoft for Startups
October 11, 2021
Find us at HLTH 2021 in Boston to connect and learn more about our to our pioneering metabolomics platform and machine learning algorithms that produce Biomarkers of Response which can differentiate drug responders from non-responders and ensure optimal treament. We are building our BoR pipeline across oncology, transplant, and neurodegeneration. Contact MfSatHLTH@microsoft.com to set up a time.
Women In Biopharma: Seven women in life sciences weigh in on the challenges facing the industry
October 8, 2021
This week, the Business Journal featured a handful of Boston-area women in the industry, both established leaders as well as those who are just breaking onto the scene, at its Women Who Lead in Life Sciences event. In the following pages, they discuss their careers, the challenges facing their industry and what needs to be done to promote women in the male-dominated field.
Olaris Appoints Nephrology and Transplant Expert Dr. Dirk Kuypers to SAB
September 30, 2021
Dr. Kuypers is Professor of Medicine and Chair of the Laboratory of Nephrology at the University of Leuven, Belgium. He is also the Head of the Department of Nephrology and Director of the Renal Transplantation Program at the University Hospitals Leuven, Belgium. Dr. Kuypers’ clinical and translational research has spanned renal allograft surveillance using protocol biopsies and biomarkers of allograft status to pre-clinical and clinical immunosuppressive therapy development. He founded the Leuven Renal Allograft Biobank, which contributes prospectively collected biological samples and clinical data to translational studies in kidney transplantation.
Olaris CEO Joins New AACR Working Group on Cancer Evolution
August 2, 2021
Why is cancer so hard to treat? How can we overcome resistance? Cancer is an everchanging disease-and many of the greatest treatment challenges are driven by clonal evolution. We must adapt to keep up!
In a great step, the AACR has formed the new Cancer Evolution working group, with Olaris CEO Dr. Liz O'Day on the Steering Committee. Co-chaired by Frank Laukien, CEO of Bruker, and Charles Swanton of the Francis Crick and UCL Cancer Institutes, this group of experts will translate cutting-edge research into new diagnostic, therapeutic, and prevention strategies.
A new way of treating cancer is coming, and biomarkers will be the guide!
Microsoft's Tom Davis: Dr. Liz O'Day brings scientific rigor to the business of precision medicine
July 13, 2021
From the laboratory to the boardroom, Tom Davis discovers how Dr. Liz O’Day applied her science career to founding biotech startup Olaris in the latest "Meet The Innovators" series.
Olaris CEO Recognized as Innovative Female Founder in Healthcare by Microsoft for Startups
July 9, 2021
When an estimated 7% of all health & life science startups are started by women, these five female founders are leading some of the most innovative companies in transforming healthcare services. Read more from Sally Ann Frank on The Record about how their startup ideas led to fast-moving businesses.
Olaris CEO Selected As 2021 Entrepreneur of the Year New England Finalist
June 10, 2021
We are honored to have Dr. Liz O'Day recognized among so many unstoppable business leaders in New England as one of the Finalists for EY Entrepreneur of The Year! For 35 years, the award has recognized game-changing entrepreneurs - those who have ushered in innovation throughout their careers and who are disrupting industries with each step they take.
Olaris BoR Technology on C-Sessions with Randall Broad
June 3, 2021
Olaris CEO and Founder Dr. Liz O'Day had the opportunity to share the origin of BoR technology with C-sessions and describe how our BoRs can be used as a tool to determine which treatment is best for each patient- even before they start therapy. Listen below to learn how Olaris BoRs in oncology can empower patients and providers to be confident in their treatment.
Olaris Welcomes Dr. Leonardo Rodrigues as VP of Artificial Intelligence and Machine Learning
May 12, 2021
In his role, Dr. Rodrigues will lead the acceleration of Olaris’ data strategy for the continued development of novel diagnostics with the potential to transform how diseases are diagnosed and treated. He will also provide critical insight enabling Olaris to streamline its technology for companion diagnostic development with biopharma partners in clinical trials.
Boston Business Journal: Olaris founder Liz O'Day works to make personalized medicine a reality
May 2, 2021
Liz O'Day has founded a for-profit biotech company, a nonprofit organization and is working hard to help the world return not only to 'some version of normal but hopefully even better.'
Olaris Announces Presentation on Metabolic Biomarkers of Response in Advanced GIST at American Association for Cancer Research (AACR) 2021 Annual Meeting
April 9, 2021
Olaris is pleased to announce the company’s presentation on the identification of metabolic signatures in plasma samples associated with therapeutic response in metastatic gastrointestinal stromal tumors (GIST) has been selected for poster presentation at the upcoming 2021 American Association for Cancer Research (AACR) annual meeting, to be held virtually April 10th - 15th.
The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, highlights the use of Olaris’ BoR platform to identify metabolic signatures correlated with overall survival and to predict response or resistance to treatment in patients with advanced GIST.
Dr. Elizabeth O'Day Selected to Join the Biological Magnetic Resonance Bank Advisory Board
March 31, 2021
Dr. O'Day is thrilled to join the BMRB advisory board to help expand the internationally renowned repository for biomolecular NMR data. Dr. O'Day will serve as a metabolomics and biotech advisor as BRMB develops additional content and tools to serve users of the repository.
Olaris Joins Microsoft for Startups
March 22, 2021
As the newest member of of the technology leader's global program aimed at helping startups scale, Olaris will be steamlining BoR development in immune response, neurodegeneration, and oncology. Olaris will also expand collaboration opportunities within biotechnology and healthcare through Microsoft's global partnership ecosystem.
Olaris CEO Featured on Catalyst Health Innovation Summit Panel
March 3, 2021
Dr. O'Day was joined by industry experts and thought leaders Joshua Weiner, Healthcare Strategy at Facebook, and Dr. Martin-Immanuel Bittner, CEO of Arctoris, to discuss biotech innovations during the pandemic and to share their insights on the future of healthcare during their panel at Cataylst HIF 2021.
World-leading Breast Cancer Oncologists Cynthia Ma MD, PhD and Massimo Cristofanilli, MD to Join Olaris Scientific and Medical Advisory Board
February 16, 2021
Olaris has appointed Dr. Cynthia Ma of Washington University in St. Louis and Dr. Massimo Cristofanilli from Northwestern Medicine to its Scientific Advisory Board and Medical Advisory Board. Dr. Ma and Dr. Cristofanilli will provide guidance on commercializing Olaris’ successful research identifying metabolic signatures for response to CDK4/6 inhibitors and building a pipeline of clinically differentiated, high-value diagnostic solutions.
Dr. Elizabeth O'Day, Olaris CEO, and Dr. Mike Pellini, Managing Director of Section 32 speak on BC panel
January 20, 2021
Dr. Elizabeth O'Day and Dr. Mike Pellini discuss how far biotechnology has come in the last decade and share their insights on how robust diagnostics will usher in the future of precision medicine. Watch their panel in the recap below.
Scientific American Top 10 Emerging Tech of 2020: Olaris CEO Discusses Microneedles
November 13, 2020
Read Olaris CEO Dr. Elizabeth O'Day's article on how microneedles could enable painless injections and blood draws in Scientific Americans Top 10 Emerging Technologies of 2020.
Olaris CEO Featured in Authority Magazine's Female Disruptors Series
November 3, 2020
"My baseline for whether disruption is ‘good’ is thinking about whether the change in the industry will have a genuinely positive impact on people’s lives. Of course, this is a subjective measure, but in the case of Olaris, you can make the strong argument that our platform for determining which patients will benefit from a specific therapy will improve the lives of millions." - Dr. Elizabeth O'Day as interviewed in Authority Magazine's Female Disruptors series aimed to feature women bringing radical change to their industry.
Olaris Presents At BU Questrom's Annual Health and Life Sciences Conference
October 30, 2020
Dr. Elizabeth O'Day discussed how Olaris leverages metabolomics and machine learning through our Biomarkers of Response platform to determine the most effective therapies for patients - providing the right drug, to the right patient, at the right time.
Olaris Honored to Recieve BostInno's 50 on Fire 2020 Award
October 26, 2020
Olaris was selected for BostInno's 50 on Fire award for our Biomarkers of Response platform to determine whether a patient will respond to certain drugs or treatments for certain types of diseases. Our technology was recognized by STAT for developing biomarker-based tests over the past year for metastatic breast cancer, metastatic gastrointestinal stromal tumors, Parkinson’s Disease and for immunosuppressive drugs given before a kidney transplant.
Olaris Featured in Node by Slush Event with Astrazeneca
October 20, 2020
Olaris joined Astrazeneca on October 20th for the first of two digital engagement events with Slush, focusing on ‘Healthcare of the future – a roadmap towards collaborative value creation’ to present our unique Biomarkers of Response platform.
Olaris Presents at Groundbreaking Cancer & Evolution Symposium
October 16, 2020
Dr. Elizabeth O'Day joined influential scientists in cancer biology and evolutionary biology, including Azra Raza, George Church, Adelene Perkins, Frank Laukien, and Denis Noble, at the first meeting of the Cancer and Evolution Symposium to present the Olaris BoR platform for assessing breast cancer patient response to CDK4/6 inhibitors to improve outcomes.
View Dr. O'Day's talk below.
Olaris CEO Panelist Speaker at The Digital Clinical Biomarkers & World CDx Summit
September 29, 2020
Dr. Elizabeth O'Day participated in an excellent panel discussion on Women and Diversity in Precision Medicine with Dr. Maria C.M. Orr (Head of Precision Medicine for Biopharmaceuticals at Astrazeneca) and Nina Green (VP and GM of Companion Diagnostics at Agilent Technologies) at the Clinical Biomarkers and World CDx Summit in September.
Increasing diversity in precision medicine must be deliberate, and the "Yes And, No But" challenge can do just that. When accepting an opportunity, suggest a colleague or individual who you think would also benefit from and contribute to the experience but may not have been offered the opportunity. If you are unable to accept, suggest someone who is less likely to be invited to go in your place!
COO Leslie Hoyt Speaker for HBA Women's Leadership Panel
September 23, 2020
Olaris CCO and COO Leslie Hoyt spoke at the Healthcare Businesswomen's Association's event "The Women’s Leadership Gap: Climbing Beyond the Broken Rung in the Career Ladder." Leslie was joined by four highly accomplished women in the science and pharmaceutical space who have climbed beyond the ‘broken rung’ in their career ladders and excelled into leadership positions, including Dr. Alita Miller (VP of Biosciences Entasis Therapeutics), Dr. Shruta Rege (Head of Regulatory Affairs at Entasis), Dr. Nerissa Kreher (CMO of Tiburio Therapeutics) and Deb Tatton (Senior VP of GCO at Parexel).
Olaris CEO Selected for Boston Business Journals 40 under 40
September 23, 2020
Dr. Elizabeth O’Day was selected for the Boston Business Journals 40 under 40 award which highlights the best and brightest professionals in the Greater Boston area.
In Her Own Words: Olaris founder Dr. Elizabeth O’Day’s biopharma company was at the crossroads of performance and pandemic
September 1, 2020
Dr. Elizabeth O’Day’s Olaris team had developed a platform that could help patients suffering from breast cancer and Parkinson’s as well as other diseases get the right drugs at the right time. And then Covid-19 hit. Read more in The Business Journals feature.
Check out our latest article on personalized medicine in the Middle East and North Africa!
August 7, 2020
Biomarkers are the fuel for precision medicine and prevention. But what happens to populations for which biomarker data is lacking? CEO and Founder Dr. Elizabeth O'Day co-authored a piece through the WEF on the potential for genomic and lifestyle studies to make for a healthier future in the Middle East and North Africa (MENA).
"The Death of Disease?"; Panel Featuring Olaris CEO Dr. Elizabeth O'Day
July 23, 2020
This summer, 32,000 people from around the world tuned into Collision, North America's fastest-growing tech conference. Dr. O'Day spoke on "The Death of Disease?" panel, where she discussed the prospects of a disease-free world.
Inspiration on the Personalized Medicine Podcast
June 25, 2020
The latest episode of the Personalized Medicine Podcast features CEO and Founder Dr. Liz O'Day discussing everything from science to comic books to business to even detailing the joys and frustrations of a western blot Available via your favorite podcast platform!
Passion and Purpose. Fireside Chat with StartUp Grind
June 24, 2020
Purpose & Passion. Check out Startup Grind's fireside chat with CEO and Founder Dr. Elizabeth O'Day on what is like to transition from academia to industry and start a company. Thank you to sponsors Google for Startups, SVB Financial Group and Brex
Xconomy Xcelerating Life Science Highlight Podcast Featuring Olaris CEO Dr. Elizabeth O'Day
June 9, 2020
The highlight reel is out from Xconomy's Xcelerating Life Sciences event. Tune in for a recap and check out minutes 18:45-21:00 to hear Olaris CEO Dr. Elizabeth O'Day discuss why the world needs precision medicine now more than ever in the COVID-19 era.
Olaris CEO Elected to Personalized Medicine Coalition Board of Directors
June 8, 2020
Dr. Elizabeth O’Day will lead personalized medicine investment and adoption efforts globally during three-year term
World Economic Forum releases final Vision Statement for Precision Medicine
May 28, 2020
Over the past year, Olaris CEO, Dr. Liz O'Day , has served on the World Economic Forum's Global Precision Medicine Council to unlock precision medicine in healthcare for all. Dr. O'Day led the task force focusing on Access and Fair Pricing. Today the World Economic Forum released the final Vision Statement for Precision Medicine! Find WEF's recommendations for advancing precision medicine globally here.
Olaris CEO, Dr. Elizabeth O'Day, contributes to USP's Trust or Consequences 2040 Report
May 22, 2020
Just weeks before COVID19 made headlines, Olaris CEO, Dr. Liz O'Day, collaborated with 100+ global experts to explore the future of medicine & healthcare. The project was a joint effort of U.S. Pharmacopeia and SupermindsMIT. A recurring theme between now and 2040 was the increasing frequency of global crises, like COVID-19. Read more in the full report, Trust or Consequences 2040, here.
BiopharmaTrend highlights 11 women entrepreneurs advancing AI in life sciences
May 18, 2020
BiopharmaTrend recently highlighted 11 women entrepreneurs from across the world, including Olaris CEO, Dr. Liz O'Day, who are solving some of healthcare's biggest problems through AI and machine learning. Read more about their game-changing research here!
Olaris CEO to Speak at Xconomy’s Xcelerating Life Sciences Boston Event
May 13, 2020
Olaris CEO Dr. Elizabeth O’Day will speak at Xcelerating Life Sciences Boston, an Xconomy virtual conference & networking event focused on biopharma’s future in digital health. Dr. O'Day will sit on the panel, “Managing the Patient in the World of Personalized Medicine.”
Olaris featured in BiopharmaTrend Q&A article, "Hacking Metabolomics With AI To Improve Clinical Research"
May 12, 2020
"Hacking Metabolomics With AI To Improve Clinical Research" Check out Olaris CEO, Dr. Liz O'Day's, recent Q&A interview with BiopharmaTrend. Dr. O'Day explains how Olaris combines metabolomics, NMR and machine learning to further precision medicine. Read the full article here!
Olaris CEO, Dr. Elizabeth O'Day, received an invitation to join the World Health Organization's Global Health Foresight Function
May 4, 2020
Invitation accepted! The World Health Organization does phenomenal work across the globe. Olaris CEO, Dr. Liz O'Day, is honored to receive an invite from the CSO Dr. Swaminathan to lend her expertise on how to plan for and execute on a healthier global future.
Olaris Biomarkers of Response platform featured in Forbes
March 31, 2020
Thank you to Forbes for chatting with Olaris CEO, Dr. Liz O'Day, about how Olaris is trying to get the right drug to the right patient at the right time.
Olaris CEO, Dr. Elizabeth O'Day, featured in Lab Manager to share how Olaris has transitioned to work from home amid COVID-19
March 30, 2020
"This is an unprecedented time in history where every single person has a role to play." Working from home and social distancing play a major role in slowing the spread of COVID-19, but this transition is not as simple for laboratory staff. Olaris CEO, Dr. Liz O'Day, shares how Olaris has pivoted to work from home for all employees and redirected scientists' work. Read more about our decision and where our focus lies now in Lab Manager's recent article.
Olaris selected to particpate in the MedTech Innovator Online Pitch event
March 24, 2020
MedTech Innovator seeks to award companies that are transforming healthcare and improving patient's lives. Dr. Liz O'Day, Olaris CEO, will pitch Olaris' metabolomics platform to a series of judges in the hopes of moving forward in the MedTech Innovator Road Tour.
Olaris CEO, Dr. Elizabeth O'Day, highlighted in Eight Roads blog as inspiring entrepreneur
March 13, 2020
In honor of National Women's Day, Eight Roads highlighted a few women entrepreneurs who inspire them. Read more about these incredibly accomplished women, including Olaris CEO, Dr. Liz O'Day, and why we need more women in entrepreneurship and venture capital.
Olaris CEO, Dr. Elizabeth O'Day, profiled in HubWeek's Change Marker series
March 11, 2020
What are Olaris' BoRs and how will they fundamentally change the way diseases are treated? Learn about our Biomarkers of Response and Olaris' mission here!
Olaris Announces Findings from Exploratory Analysis of Biomarkers that Predict Patient Responsiveness to Trastuzumab Therapy
March 2, 2020
Olaris’ metabolite profiling platform and machine learning algorithms have the potential to accurately indicate whether HER2-positive metastatic breast cancer patients will respond to trastuzumab therapy.
Olaris Abstract Accepted for Poster Presentation at ENC
February 13, 2020
Olaris' will be presenting a poster at the ENC! The Experimental NMR Conference features innovative research in NMR spectroscopy and Olaris is very excited to share our recent studies on the power of NUS 13C 1H HSQC NMR. Learn more about the conference below.
Olaris Announces Grant from The Michael J. Fox Foundation for Parkinson’s Research
February 11, 2020
Initial project focus on uncovering metabolic signatures associated with neurodegenerative disease to provide deeper insight into mechanisms involved in Parkinson’s and its progression.
Olaris CEO, Dr. Elizabeth O'Day, featured in DRG blog " Startup Scouring The Metabolome for Precision Medicine Biomarkers"
February 6, 2020
Want to learn more about Olaris and the power of metabolomics? Olaris CEO, Liz O'Day, discusses Olaris' platform and how metabolic biomarkers have the potential to change the way cancer is treated in the DRG blog.
Olaris CEO, Dr. ELizabeth Day, and COO, Leslie Hoyt, travel to San Fransisco for JPM
January 13, 2020
Olaris CEO, Liz O'Day, and COO, Leslie Hoyt, had a fantastic time this week at J.P. Morgan Healthcare conference in San Fransisco! It is a great opportunity to meet with new and old friends to share Olaris' story and learn from other innovators in healthcare.
Olaris is Presenting a Poster at the San Antonio Breast Cancer Symposium!
December 12, 2019
Olaris is thrilled to present at the SABCS! We are excited to learn from the world's top breast cancer oncologists and share the results of our recent study, "Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer." Learn more about the conference here.
Olaris CEO, Dr. Elizabeth O'Day, interviewed for US Pharmacopeia's TrustTV to discuss trust in healthcare
November 14, 2019
US Pharmacopeia will be releasing the series, TrustTV, to highlight trust, or lack thereof, in healthcare by interviewing multiple stakeholders in the healthcare system. Dr. Liz O'Day sat down with Dr. Dhruv Khullar to share her thoughts on the importance of trustworthiness in healthcare. The interview will be released in early 2020.
Olaris COO, Leslie Hoyt, is attending the Personalized Medicine Conference!
November 13, 2019
Olaris is a proud member of the Personalized Medicine Coalition, an innovative group working to advance precision medicine in today's health systems. This week they are hosting the Personalized Medicine Conference to bring together the world leaders in precision medicine. Learn more about the conference here.
Olaris CEO, Dr. Elizabeth O'Day, travels to Dubai for the World Economic Forum Annual Meeting of the Global Future Councils
November 6, 2019
As the co-chair of the Global Future Council on Biotechnology, Dr. O'Day worked with this passionate team to discuss patient-focused policy changes that can increase biotechnology innovation around the world. Check out the discussions in Dubai here.
Meet the Olaris Scientific Advisory Board!
October 21, 2019
Olaris is honored to have these four world leading experts in NMR, diagnostics, metabolomics and data on our SAB. One of our core vales is to "always strive for better" and there is no doubt these SAB members will continuously push us to do just that. Thank you to Dr. Gerhard Wagner, Stan Lapidus, Dr. Bob Powers and Monty Kothiwale for being part of the Olaris team.
Olaris CEO, Dr. Elizabeth O'Day, featured in Life Science Leaders magazine article
October 3, 2019
Check out Life Science Leader's article about Olaris CEO, Dr. Liz O'Day, and PanTher Therapeutics CEO, Dr. Laura Indolfi's experience with the MLSC MassNextGen program and how it helped them grow their network and business.
Olaris finds a new home in the AstraZeneca Boston BioHub!
October 1, 2019
Olaris has been invited to the AstraZeneca Incubator Labs at the Boston BioHub! We can't wait to join their community in Waltham, MA starting October 1st.
Olaris completes Series A Financing Round
September 30, 2019
We are proud to announce Olaris has completed its Series A funding led by Innospark Ventures. Our team's talent, passion, commitment and moral compass will continue define us in the next phase of Olaris' journey.
Olaris presents poster at the San Antonio Breast Cancer Symposium
September 25, 2019
Olaris has been studying trastuzumab drug response in metastatic breast cancer patients and we are very proud to share our findings with everyone at SABCS, one of the largest breast cancer conferences in the US!
"Give Me Inspiration! The Paradigm Shift" : Olaris CEO, Dr. Elizabeth O'Day, talks with Master of Churchill College
September 16, 2019
"Give Me Inspiration! The Paradigm Shift" is a series of conversations with the Master of Churchill College, Professor Dame Athene Donald, that focuses on women leaders and what motivates them to continue to break down barriers. Olaris CEO and Churchill College alum, Dr. Liz O'Day, has been invited to participate in New York City next week.
Olaris CEO to sit on EY Women Leading Innovation Breakfast panel
September 12, 2019
The EY Women Leading Innovation Breakfast is next week and Olaris CEO, Dr. Liz O’Day, is sitting on a panel with four other incredible women changing the game in the health science field. These women will discuss their experience in the industry as well as how to showcase more women at the forefront of innovation.